espi SOPHARMA AD 2023-07-14 16:12

POLISH FINANCIAL SUPERVISION AUTHORITY
		UNI - EN REPORT No		88	/	2023
Date of issue:	2023-07-14
Short name of the issuer
SOPHARMA AD
Subject
Initiation of negotiations for potential acquisition of Pharmanova, Republic of Serbia
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
“Sopharma” AD (the Company) ) notifies that in implementation of a decision of the Board of Directors after a detailed analysis and negotiations, "Sopharma" AD signed a contract for the phased acquisition of the Serbian pharmaceutical manufacturer Pharmanova within two years. The deal is subject to approval by the Serbian Competition Commission and will start with the acquisition of 25% of the Company, followed by the acquisition of 50% after one year and 25% after two years, respectively. Pharmanova sells its products with leading consumer brands in the markets of Serbia, Bosnia, Montenegro and Macedonia. For 2022, the company's net sales revenues amount to ТEUR 10 225.
Annexes
File			Description
SFA_Pharmanova_14072023_espi_88.pdf			Initiation of negotiations for potential acquisition of Pharmanova, Republic of Serbia